Pediatrics Hematology and Oncology, Hospital Austral, Pilar, Argentina.
Service of Hematology/Oncology, Hospital J.P Garrahan, Buenos Aires, Argentina.
Pediatr Blood Cancer. 2022 Oct;69(10):e29748. doi: 10.1002/pbc.29748. Epub 2022 May 20.
The ongoing coronavirus 2019 disease (COVID-19) pandemic strained medical systems worldwide. We report on the impact on pediatric oncology care in Latin American (LATAM) during its first year.
Four cross-sectional surveys were electronically distributed among pediatric onco-hematologists in April/June/October 2020, and April/2021 through the Latin American Society of Pediatric Oncology (SLAOP) email list and St Jude Global regional partners.
Four hundred fifty-three pediatric onco-hematologists from 20 countries responded to the first survey, with subsequent surveys response rates above 85%. More than 95% of participants reported that treatment continued without interruption for new and active ongoing patients, though with disruptions in treatment availability. During the first three surveys, respondents reported suspensions of outpatient procedures (54.2%), a decrease in oncologic surgeries (43.6%), radiotherapy (28.4%), stem cell transplants (SCT) (69.3%), and surveillance consultations (81.2%). Logistic regression analysis showed that at the beginning of the first wave, participants from countries with healthcare expenditure below 7% were more likely to report a decrease in outpatient procedures (odds ratio [OR]: 1.84, 95% CI: 1.19-2.8), surgeries (OR: 3, 95% CI: 1.9-4.6) and radiotherapy (OR: 6, 95% CI: 3.5-10.4). Suspension of surveillance consultations was higher in countries with COVID-19 case fatality rates above 2% (OR: 3, 95% CI: 1.4-6.2) and SCT suspensions in countries with COVID-19 incidence rate above 100 cases per 100,000 (OR: 3.48, 95% CI: 1.6-7.45). Paradoxically, at the beginning of the second wave with COVID-19 cases rising exponentially, most participants reported improvements in cancer services availability.
Our data show the medium-term collateral effects of the pandemic on pediatric oncology care in LATAM, which might help delineate oncology care delivery amid current and future challenges posed by the pandemic.
2019 年冠状病毒病(COVID-19)大流行使全球医疗系统承受压力。我们报告了拉丁美洲(LATAM)儿科肿瘤学护理在其第一年受到的影响。
2020 年 4 月/6 月/10 月和 2021 年 4 月,通过拉丁美洲儿科肿瘤学会(SLAOP)电子邮件列表和圣裘德全球区域合作伙伴,向 453 名儿科肿瘤血液学家电子分发了四份横断面调查。
来自 20 个国家的 453 名儿科肿瘤血液学家对第一份调查做出了回应,随后的调查回应率均高于 85%。超过 95%的参与者报告说,新的和正在进行的患者的治疗没有中断,尽管治疗的可及性受到了干扰。在前三轮调查中,受访者报告说门诊程序暂停(54.2%)、肿瘤手术减少(43.6%)、放疗减少(28.4%)、干细胞移植(SCT)减少(69.3%)和监测咨询减少(81.2%)。逻辑回归分析显示,在第一波开始时,医疗支出低于 7%的国家的参与者更有可能报告门诊程序减少(比值比[OR]:1.84,95%CI:1.19-2.8)、手术减少(OR:3,95%CI:1.9-4.6)和放疗减少(OR:6,95%CI:3.5-10.4)。在 COVID-19 病死率超过 2%的国家,监测咨询暂停的比例更高(OR:3,95%CI:1.4-6.2),在 COVID-19 发病率超过每 10 万人 100 例的国家,SCT 暂停的比例更高(OR:3.48,95%CI:1.6-7.45)。矛盾的是,在 COVID-19 病例呈指数级增长的第二波开始时,大多数参与者报告说癌症服务的可及性有所改善。
我们的数据显示了大流行对拉丁美洲儿科肿瘤学护理的中期影响,这可能有助于描绘在当前和未来大流行带来的挑战中提供肿瘤学护理的情况。